CriticalProkinetic, 5-HT4 serotonin receptor agonist (withdrawn EU/US)×First-generation antipsychotic, diphenylbutylpiperidine derivative
Updated · Methodology
Mechanism
Pimozide prolongs the QT interval on the electrocardiogram, so an additive effect on QT can be expected with other QT-prolonging drugs (pimozide label, US Food and Drug Administration, FDA). The Spanish pimozide summary of product characteristics (SmPC) names cisapride among drugs known to prolong the QT interval (pimozide SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). In the liver, pimozide goes mainly through CYP3A4 and CYP2D6 and to a lesser extent through CYP1A2. Higher pimozide levels may increase the risk of QT prolongation (pimozide SmPC, AEMPS). The pimozide documents do not describe cisapride as an inhibitor of these enzymes, and they give no data on how pimozide and cisapride affect each other's levels.
Symptoms
QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). A ventricular arrhythmia causes sudden strong palpitations, dizziness or fainting and can lead to cardiac arrest. With long-term therapeutic doses of pimozide and in overdose, very rare cases of QT prolongation, ventricular arrhythmias and torsade de pointes have been reported, even in people without risk factors. Ventricular tachycardia and ventricular fibrillation, sometimes fatal, and very rare cases of sudden death and cardiac arrest have also been reported (pimozide summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Severe arrhythmias may be accompanied by low blood pressure and circulatory collapse (pimozide SmPC, AEMPS, overdose section).
Management
The combination is contraindicated. The Spanish pimozide summary of product characteristics (SmPC) contraindicates pimozide with drugs known to prolong the QT interval and names cisapride among them (pimozide SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US pimozide label contraindicates other QT-prolonging drugs and gives only examples, and cisapride is not among them (pimozide label, US Food and Drug Administration, FDA). Cisapride is not in the Spanish medicines register CIMA, so the pimozide documents set the level of risk. If a person takes cisapride obtained in another country, do not prescribe pimozide with it (pimozide SmPC, AEMPS). No document states how long to wait after stopping pimozide before starting cisapride. The mean elimination half-life of pimozide in people with schizophrenia is about 55 hours (pimozide SmPC, AEMPS). Record an electrocardiogram (ECG) before starting pimozide and periodically during treatment. If repolarisation changes or arrhythmias appear, review the need for pimozide and lower the dose or stop it. Stop pimozide if the QT or corrected QT interval (QTc) exceeds 500 ms (pimozide SmPC, AEMPS). Pimozide is contraindicated in known low potassium or magnesium and in clinically significant bradycardia. Avoid diuretics, especially those that lower potassium (pimozide SmPC, AEMPS). The US label calls for correcting low potassium before starting pimozide and keeping potassium normal during treatment (pimozide FDA label).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Pimozide tablets, USP (ANI Pharmaceuticals) – prescribing information (2026)– FDA label, ANI Pharmaceuticals, DailyMed setid 4e954fc2-fdff-486c-beb6-2b8ace717081, version 3, 07/2026, INDICATIONS AND USAGE, CONTRAINDICATIONS, PRECAUTIONS: Drug Interactions
- AEMPS: Ficha técnica: Orap (pimozida) (nº registro 49503), secciones 4.3 y 4.5 (2026)– AEMPS, CIMA, nº registro 49503, revisión 10/2026, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Orap (pimozida) (nº registro 49503), sección 4.3 (2026)– AEMPS, CIMA, nº registro 49503, revisión 10/2026, secciones 4.3, 4.4 y 4.5